All the complement inhibitor therapies for PNH could face a tough time competing with new oral therapies that are also reaching or approaching potential market launch. That includes Novartis ...

The question is whether the added convenience offered by crovalimab will be enough to carve out a niche for the drug in the increasingly crowded PNH market. AZ is working hard to build a market ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

A novel drug combination, improvements in quality of life, and breakthrough hemolysis control are among the clinical highlights in paroxysmal nocturnal hemoglobinuria (PNH) presented at the 2024 ...

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net ...